Table of contents
The following summarized guidelines for the management of tardive dyskinesia are prepared by our editorial team based on guidelines from the American Academy of Neurology (AAN 2013).
Switching to atypical antipsychotics: insufficient evidence to support or refute treatment of tardive syndromes by withdrawing causative agents or switching from typical to atypical dopamine receptor blocking agent.
More topics in this section
Amantadine and tetrabenazine
Agents with no evidence for efficacy